Evidence map›Paper›PMID 40297615›Full record

ArticleInternational journal of general medicine2025

To Evaluate the Diagnostic Performance of Rapid on-Site Evaluation (ROSE) in Combination with Endobronchial Ultrasound (EBUS) for Pulmonary Lesions.

Shan Xu, Qianlong Yin, Jisong Zhang, Xiaoling Xu, Enguo Chen, Kejing Ying

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of general medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. A rare cause of a solitary pulmonary mass.Breathe (Sheffield, England) · 2026
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Shan XuRespiratory and Critical Care Medicine, Regional Medical Center for National Institute of Respiratory Disease, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, People's Republic of China.
Qianlong YinRespiratory and Critical Care Medicine, Sir Run Run Shaw Hospital Affiliated to Zhejiang University School of Medicine, Xinjiang Corps Alaer Hospital, Alaer, People's Republic of China.
Jisong ZhangRespiratory and Critical Care Medicine, Regional Medical Center for National Institute of Respiratory Disease, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, People's Republic of China.
Xiaoling XuRespiratory and Critical Care Medicine, Regional Medical Center for National Institute of Respiratory Disease, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, People's Republic of China.
Enguo ChenRespiratory and Critical Care Medicine, Regional Medical Center for National Institute of Respiratory Disease, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, People's Republic of China.
Kejing YingRespiratory and Critical Care Medicine, Regional Medical Center for National Institute of Respiratory Disease, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Currently, Endobronchial ultrasound (EBUS) and rapid on-site evaluation (ROSE) are extensively utilized in the clinical practice of respiratory medicine. The combined diagnostic approach has been shown to enhance the clinical diagnostic accuracy; however, certain controversies remain. Methods: This study included 200 patients who underwent endobronchial ultrasound combined with transbronchial lung biopsy with a guide sheath (EBUS-GS-TBLB) or endobronchial ultrasound combined with transbronchial needle aspiration (EBUS-TBNA) and received histopathological diagnoses at the Bronchoscopy Department, from January 2021 to January 2022. Of these, 168 patients were assigned to the ROSE group and 32 to the non-ROSE group. The diagnosis rates of EBUS-GS-TBLB and EBUS-TBNA, both with and without ROSE, along with the secondary biopsy rate, complication probability, and mean number of biopsies, were compared to analyze the differences between tumors and non-tumors. The safety of EBUS-GS-TBLB and EBUS-TBNA was also evaluated. Results: The overall diagnostic accuracy was 85.71% in the ROSE group and 65.62% in the non-ROSE group. The diagnostic accuracy of the ROSE group was significantly higher than that of the non-ROSE group (P < 0.05). Compared to the non-ROSE group, the rate of secondary biopsy in the ROSE group was significantly reduced (P < 0.05), particularly in non-tumor cases. However, there was no significant difference in the incidence of complications and the average number of biopsies between the two groups (P > 0.05). Compared to the EBUS-GS-TBLB group, the EBUS-TBNA group showed a significantly lower incidence of complications and fewer biopsies (P < 0.05). Conclusion: The integration of ROSE with EBUS enhanced the diagnostic rate and reduced the need for secondary examinations in the biopsy diagnosis of lung lesions, particularly in the definitive diagnosis of non-neoplastic lesions. The combination of ROSE technology appears to be more advantageous. Compared to EBUS-GS-TBLB, EBUS-TBNA demonstrated a lower incidence of complications and fewer biopsies.

Indexed as

diagnostic efficacylung biopsypulmonary lesionsrapid on‐site evaluationsafety comparisonultrasound bronchoscopy

Identifiers

PMID40297615
PMCPMC12036591

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.